autologous blinatumomab-expanded T cells

{
  "id": "MLC-T-ONC-011519",
  "term": "autologous blinatumomab-expanded T cells",
  "field": "Oncology and biomedicine",
  "definition": "A preparation of autologous, peripheral blood-derived polyclonal activated T cells that have been expanded and activated ex-vivo using blinatumomab and recombinant human IL2 (rhIL-2) and depleted of contaminating CD19+ tumor cells, with potential immunomodulating activity. Upon administration, these blinatumomab-expanded T cells (BET), composed of functional polyclonal CD4+ and CD8+ T cells and mostly effector and central memory cells, may induce immunological recovery. BET cell expansion leads to the lysis and elimination of contaminating CD19+ tumor cells. The elimination of contaminating tumor cells is important in the treatment of non-Hodgkin CD20 + indolent lymphoma (iNHL) and chronic lymphatic leukemia (CLL).",
  "synonyms": [
    "BET",
    "blinatumomab-cultured T cells",
    "blinatumomab-expanded peripheral blood-derived T cells",
    "blinatumomab-expanded T cells"
  ],
  "references": [
    "National Cancer Institute Thesaurus"
  ],
  "url": "https://mlchart.com/terminology/oncology/autologous-blinatumomab-expanded-t-cells/"
}